洛伦德罗斯塔特在患有无控高血压的患者中的有效性和安全性
Luke J Laffin1,2, Branko Kopjar3, Carrie Melgaard2
1Section of Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland.
The New England journal of medicine
|April 23, 2025
概括
洛伦德洛斯塔特显著降低了无控高血压患者的血压. 这种阿尔多氨酸合成酶抑制剂在随机试验中显示出有效性和可管理的安全性.
科学领域:
- 心血管医学 心血管医学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔多激素失调是高血压发展的关键因素.
- 作为阿尔多氨酸合成酶抑制剂的洛伦德洛斯塔特,对高血压的临床数据有限.
- 失控和耐治疗的高血压仍然是一个重大的临床挑战.
研究的目的:
- 评估洛伦德罗斯塔特在患有未控制高血压的患者的疗效和安全性.
- 评估与安慰剂相比,洛伦德罗斯塔特的降血压效果.
主要方法:
- 一个多中心,双盲,随机,安慰剂控制的试验,涉及285名患有失控高血压的参与者.
- 参与者接受了一种标准化的抗高血压疗法,然后随机分配到安慰剂或两种洛伦德罗斯塔特剂量策略 (稳定剂量或剂量调整).
- 主要终点是12周内24小时平均缩血压的变化.
主要成果:
- 洛伦德洛斯塔特组在12周内,与安慰剂相比,静脉压下降幅度更大 (安慰剂调整后的变化为-7.9毫米血压和-6.5毫米血压).
- 观察到早期的疗效,在4周后,在组合洛伦德洛斯塔特组中,与安慰剂调整后的缩血压降低为-5.3 mm Hg.
- 不良事件,包括水平升高,是罕见的,在洛伦德洛斯塔特组之间是可比的.
结论:
- 洛伦德罗斯塔特有效地降低了患者的24小时平均血压不受控制和耐治疗的高血压.
- 与安慰剂相比,该药物与更大的血压降低有关.
- 洛伦德洛斯塔特为治疗耐药高血压提供了一个潜在的新疗法选择.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
316
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
316
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
384
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
384
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
539
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
539
01:33Hormonal Regulation
32.7K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.7K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
443
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
443
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
479
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
479